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AbstrAct
Several guidelines on diagnosis and treatment of thyroid nodules and cancer have recently 
been published. However, recommended practices are not always appropriate to different set-
tings or countries. The aim of this consensus was to develop Clinical Guidelines for evaluation 
and management of patients with thyroid nodules applicable to Latin American countries. The 
panel was composed by 13 members of the Latin American Thyroid Society involved with re-
search and management of thyroid nodules and cancer from different medical centers in Latin 
America. The consensus was produced based on the expert opinion of the panel with use of 
principles of evidence-based medicine. Following a group meeting, a first draft based on the ex-
pert opinion of the panel was elaborated and later circulated among panel members for further 
revision. After revision, this document was submitted to all LATS members for commentaries 
and considerations and finally revised and refined by the authors. The final recommendations 
represent state of the art on management of thyroid nodules applied to all Latin American coun-
tries. Arq Bras Endocrinol Metab. 2009;53(9):1167-75
Keywords
Thyroid nodule; thyroid ultrasonography; thyroid aspiration biopsy; radioactive iodine therapy
resumo
Vários consensos têm sido publicados acerca do diagnóstico e do tratamento de nódulos e cân-
cer da tireoide. Entretanto, as recentes recomendações nem sempre são apropriadas para di-
ferentes regiões ou países. O objetivo deste trabalho foi oferecer uma série de recomendações 
para a avaliação e conduta de pacientes portadores de nódulos tireoideos aplicáveis a todos os 
países da América Latina. O trabalho foi realizado por um comitê composto por 13 membros 
da Sociedade Latino-Americana de Tireoide envolvidos com pesquisa e manejo de pacientes 
portadores de nódulos e carcinoma diferenciado da tireoide, de diferentes centros médicos da 
América Latina. As recomendações foram estabelecidas, após consenso, utilizando as opiniões 
especializadas de cada membro e os princípios da medicina baseada em evidência. Após a 
primeira reunião do grupo, um primeiro documento foi elaborado e encaminhado a todos os 
membros para revisão. Posteriormente, o documento foi enviado aos membros da Sociedade 
Latino-Americana de Tireoide para avaliação, sugestões e comentários. A versão final, elabora-
da após refinada revisão de todos os autores, representa o estado da arte no diagnóstico e na 
conduta de nódulos tireoideos, aplicáveis a todos os países da América Latina. Arq Bras Endocrinol 
Metab. 2009;53(9):1167-75
Descritores
Nódulo da glândula tireoide; ultrassonografia da tireoide; citologia aspirativa da tireoide; radioiodoterapia
Correspondence to:
Rosalinda Camargo
Rua Mirassol, 216, ap. 82
04044-010 – São Paulo, SP, Brasil
ryasato@uol.com.br
Received on Mar/16/2009 
Accepted on Oct/10/2009
1 Faculdade de Medicina da 
Universidade de São Paulo, 
São Paulo, SP, Brasil
2 Cayetano Heredia Peruvian 
University, Lima, Peru
3 Faculdade de Medicina da 
Universidade de Santo Amaro 
(Unisa), São Paulo, SP, Brasil
4 Ramos Meija Hospital, 
Buenos Aires, Argentina
5 “Dr. A. Oñativia” Hospital, 
Salta, Argentina
6 University of Chile, Santiago, Chile
7 University of Buenos Aires, 
Buenos Aires, Argentina
8 Universidade Federal do 
Rio de Janeiro (UFRJ), Rio 
de Janeiro, RJ, Brasil
9 Faculdade de Ciências Médicas, 
Universidade Estadual de Campinas 
(Unicamp), Campinas, SP, Brasil
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
1168 Arq Bras Endocrinol Metab. 2009;53/9
LATS recommendations for thyroid nodules
IntroDuctIon
It is estimated that around 10% of adults have palpable 
thyroid nodules. The overall incidence and clinical fea-
tures of these nodules is influenced by age and level of 
iodine intake, with a particularly high incidence seen in 
iodine deficient areas (1,2). The major objective in the 
evaluation of a nodule is the exclusion of malignancy. 
The risk of malignancy in a thyroid nodule varies be-
tween 5% and 10% in iodine-sufficient countries, and 
the amount of iodine supplemented in table salt can 
influence this incidence (3).
Programs of table salt iodination in many Latin 
American countries have produced important varia-
tions in iodine intake over the past few decades, and 
the impact of these changes on the behavior of thyroid 
nodules and cancer is still largely unknown (4). New 
imaging technologies, especially ultrasonography (US), 
have improved the sensitivity for detection of thyroid 
cancer, which is now often found incidentally on ima-
ging studies performed for other indications. This has 
led to the identification of many patients with micros-
copic papillary thyroid cancers mostly without clinical 
significance (5,6).
A set of recommendations for evaluation and ma-
nagement of patients with thyroid nodules has been 
developed in consensus by 13 members of the Latin 
American Thyroid Society (LATS). This panel was 
composed by individuals involved in research and ma-
nagement of thyroid nodules and cancer from distinct 
reference medical centers in Latin America to reflect 
different practice patterns. A first questionnaire asses-
sing the most important issues on the subject was first 
discussed among panel members and a draft document 
based on the expert opinion of the panel’s participants 
as well as on previously published information, was ela-
borated and circulated among panel members for fur-
ther revision. This document was subsequently sent to 
all LATS members for comments and discussion and, 
finally, revised and refined in consensus by panel mem-
bers. These final recommendations aim to represent the 
state of the art on thyroid nodule management applied 
to Latin American countries. 
DIAgnosIs AnD mAnAgement of thyroID 
noDules
The widespread use of cross-sectional imaging and the 
large availability of neck US have improved the sensiti-
vity for detection of thyroid lesions and contributed to 
an increasing number of patients diagnosed with non-
palpable thyroid nodules. These incidentally discovered 
nodules share a similar risk of malignancy with palpable 
nodules of similar size. In general, only nodules larger 
than 1 cm should be evaluated with diagnostic tests, 
since malignant nodules ≥ 1 cm have more aggressive 
clinical and histopathological characteristics compared 
with smaller ones. A strong association between cancer 
size and aggressiveness has been clearly demonstrated 
in patients with large papillary carcinomas and the rela-
tive risk of cancer-related death is reported to increase 
1.4-fold for each 1 cm increment in tumor size (7).
Also, a progressive increase in recurrence and cause-
specific death rates has been reported in patients with 
malignant lesions progressing in size from < 1 cm to 
1-4 cm and > 4 cm (8,9). Rossi and cols. (10) have 
reported that patients with cancers between 1.1 and 
2 cm have a higher prevalence of extrathyroidal inva-
sion, lymph node metastases and distant metastases at 
diagnosis compared with those with tumors of smaller 
size. The recurrence rate for these patients is almost 
threefold higher compared with patients with malig-
nant tumors measuring 1 cm or less. The group with 
larger cancers in this study had more aggressive clinical 
and histopathological characteristics than those with 
size smaller than 1.1 cm (10).
The panel recommends that thyroid nodules larger 
than 1 cm should be evaluated with diagnostic tests. 
history and physical examination
All patients with thyroid nodules should be evaluated 
with complete history and physical examination with 
attention focused on the neck. Most thyroid carcino-
mas are silent and do not show any peculiar clinical or 
anamnestic feature. Rapid nodular growth, hoarseness, 
presence of palpable cervical lymph nodes, vocal cord 
paralysis, and fixation of the nodule to surrounding tis-
sues are suggestive signs of malignancy. Patients with 
thyroid nodules and history of total body irradiation 
for bone marrow transplantation or head and neck irra-
diation are at higher risk for malignancy (11). A fami-
ly history of a first-degree relative with thyroid cancer 
should be carefully assessed, considering the occurren-
ce of familial non-medullary thyroid cancer (12). 
laboratory evaluation 
Serum thyroid stimulating hormone (TSH) should be 
determined at the initial evaluation in all patients pre-
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senting with thyroid nodule. This test is very useful in 
identifying subtle thyroid dysfunction due to the high 
sensitivity of the TSH assay. If TSH levels are found 
to be outside the normal range, further investigation 
with measurement of thyroid peroxidase antibodies 
and free thyroxine (FT4) levels should be conducted. 
Serum thyroglobulin (Tg) is not a sensitive tool to 
determine the etiology of thyroid nodules; therefore, 
measurement of Tg should not be routinely perfor-
med (13). 
Although many studies have recommended mea-
surement of calcitonin levels in patients with thyroid 
nodules for exclusion of medullary thyroid cancer, the 
cost-effectiveness of this investigation is still unclear. 
However, serum calcitonin measurement is warranted 
when there is family history of medullary thyroid can-
cer, multiple endocrine neoplasia type 2 (MEN 2) or 
pheochromocytoma. Levels above 100 pg/mL are hi-
ghly suggestive of medullary carcinoma (14,15). 
The panel recommends TSH determination at the ini-
tial evaluation in all patients presenting with thyroid no-
dule. The panel also recommends calcitonin measurement 
if family history suggests medullary thyroid cancer. 
thyroid ultrasonography
Thyroid US is very accurate and sensitive for detection 
of thyroid nodules, although its ability to differentia-
te benign and malignant tumors is somewhat limited. 
This method measures the dimensions of nodules with 
great precision, identifies characteristics of the nodule, 
and evaluates diffuse parenchymal changes. It is nonin-
vasive, relatively inexpensive, and able to identify non-
palpable nodules and nodules that are not detected by 
isotope scanning or other imaging techniques. Both 7.5 
and 12 MHz linear transducers accurately detect and me-
asure thyroid nodules and are adequate to perform ultra-
sound-guided fine-needle aspiration biopsy (US-FNAB). 
These transducers are also acceptable for postoperative 
lymph node surveillance in patients with thyroid cancer.
Thyroid US should be performed in patients with 
palpable solitary nodules, multinodular goiter, history 
of external neck irradiation, and history of familial 
thyroid cancer or MEN 2 for detection of non-palpable 
nodules. However, due to its high sensitivity and rela-
tively low specificity, thyroid US should not be used as 
a screening test in the general population. In patients 
with a solitary nodule or with few well-separated nodu-
les, each nodule should be thoroughly described. The 
report should include a description of the position that 
each nodule occupies within the thyroid, the three-
dimensional measurements (longitudinal, anteroposte-
rior and laterolateral), echotexture (solid, mixed, cystic 
or cystic with projecting solid mural mass), echogeni-
city (anechoic, isoechoic, hypoechoic, or hyperechoic), 
characteristics of the margins, presence of peripheral 
halo, presence of internal calcifications (micro or ma-
crocalcifications) and presence of cervical lymph node 
enlargement.
When multiple nodules are found, a detailed des-
cription should be given of the nodules bearing ultra-
sonographic features associated with malignancy: hypo-
echogenicity in solid nodules, microcalcifications and 
irregular margins. In this case, care should be taken to 
avoid describing only the largest nodule (16-18). 
The characteristics of the margins of the nodule 
and the echogenicity, or the nodular shape and the 
echogenicity have been shown to be suitable criteria 
to suggest the pathological diagnosis. The best com-
promise between the risk of missing carcinomas of 
potential clinical aggressiveness and the need to avoid 
unnecessary procedures is probably to use FNAB on 
nodules with at least one of the following components: 
microcalcifications, blurred margins, or hypoechoic 
pattern (19,20).
Color and power Doppler sonography have been wi-
dely evaluated as diagnostic tools for detecting thyroid 
cancer. Many studies have observed that neoplastic 
nodules (adenomas and carcinomas) contain intra-
nodular flow signals while the majority of the colloid 
nodules are either avascular or have halo flow signals 
only (21-23). 
In contrast, other studies have reported that cer-
tain characteristics on Doppler US including vascular 
pattern, resistive index (RI) and maximal systolic velo-
city (MSV) are not useful parameters for distinguishing 
malignant from benign solid nodules (24-26). These 
characteristics, therefore, should not be used as diag-
nostic tools to determine which nodules should under-
go FNAB (27). 
The panel recommends US examination in all pa-
tients with suspected thyroid nodules, multinodular goi-
ter, history of external neck irradiation, and history of 
familial thyroid cancer or MEN 2. In the opinion of the 
panel, nodular characteristics on color Doppler alone, in-
cluding vascular pattern, RI and MSV values, are not 
useful parameters for distinguishing malignant from be-
nign thyroid nodules. 
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THYROID NODULE
(palpable or incidentally 
discovered)
TSH 
Normal or increased
TSH 
Suppressed
US /Thyroid131 I 
scintigraphy
US/palpation-guided FNAB
(Depending on the size of 
the nodule and presence of 
other nodules in the US)
US
Hot nodule
Benign Indeterminate
Follow-up
with or without 
medical treatment
Close follow-up/ 
Surgery
Surgery Repeat guided 
US-FNAB
Unsatisfactory
Close follow-up/ 
Surgery
Suspicious or malignant Unsatisfactory
Radioiodine 
treatment/Surgery
figure 1. Algorithm for diagnosis and management of palpable and incidentally discovered thyroid nodules.
scintigraphy
Thyroid scintigraphy should be performed in patients 
with single thyroid nodules and suppressed TSH, or 
in those with large toxic or nontoxic multinodular 
goiter (28). 
other imaging techniques
Magnetic resonance imaging (MRI), positron emis-
sion tomography (PET) with 18-fluorodeoxyglucose 
(FDG) and computed tomography (CT) are not re-
commended for routine examination of thyroid no-
dules, although, in some cases, non-contrast CT and 
MRI may add information to anatomic visualization 
not provided by US or radiography (29). Non-contrast 
CT may be indicated for large multinodular goiters that 
appear to extend into the upper mediastinum, particu-
larly in elderly subjects.
Routine use of other imaging studies (PET, CT and 
MRI) is not recommended.
fine-needle aspiration biopsy (fnAb)
All solid and solitary nodules ≥ 1 cm should be evalua-
ted with FNAB. The procedure may be performed by 
free hand in palpable nodules, providing other nodules 
> 1 cm have been excluded by US. 
US-FNAB is recommended in non-palpable nodu-
les and in nodules with cystic changes. It allows a more 
precise and adequate sampling and is associated with a 
lower rate of false-negative results, thus improving glo-
bal diagnostic accuracy in the preoperative selection of 
thyroid cancer (30). 
Nodules < 1 cm may be followed yearly by US only. 
In case there is US evidence of growth, extracapsular 
invasion or presence of suspicious cervical lymph no-
des, the nodule should also be evaluated by US-FNAB. 
Patients with a family history of medullary carcinoma 
or MEN 2 should also be evaluated with US-FNAB. 
In a multinodular gland in which autonomous no-
dules have been detected on scintigraphy, US-FNAB 
should be considered for iso- or hypofunctioning no-
LATS recommendations for thyroid nodules
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dules. In this case, the choice of nodules to be aspirated 
should rely on suspicious US characteristics rather than 
size. Those with suspicious US features should be biop-
sied, preferentially. 
All solid and solitary nodules ≥ 1 cm should be eva-
luated with FNAB. Nodules < 1 cm should be evaluated 
by fine-needle aspiration biopsy (FNAB) only in patients 
with history of familial thyroid cancer, MEN 2, cervical 
irradiation during childhood, or suspicious ultrasound 
findings. In a multinodular gland, nodules with suspi-
cious US features should be preferentially biopsied. 
cytologIcAl clAssIfIcAtIon of thyroID 
noDules 
The accuracy of thyroid aspiration cytology, a proce-
dure which depends largely on the experience of the 
cytopathologist, may vary among different centers and 
even within the same institution (31). 
The panel recommends that aspirates be interpreted 
by experienced cytopathologists according to the follo-
wing cytological criteria:
benign
•	 Colloid nodules: aspirates with abundant colloid, 
sheets and follicular groupings of cells with regu-
lar small nuclei.
•	 Hyperplasia within a nodular goiter: sheets and 
follicular groupings of cells with regular nuclei 
and scant colloid.
•	 Lymphocytic thyroiditis: abundant lymphocytes 
are present and may vary in size from normal, 
small lymphocytes to larger, activated lym-
phocytes.
Indeterminate (follicular pattern)
•	 Follicular neoplasms (follicular and oncocytic cell). 
•	 Occasional hyperplastic or adenomatoid nodules 
within a multinodular goiter in which a micro-
follicular focus has been sampled by chance. 
The smear patterns of hypercellular adenomatous 
nodules, microfollicular adenoma, follicular carcinoma 
and follicular variant of papillary carcinoma overlap. 
Cytopathology includes aspirates with high-to-mode-
rate cellularity with hypertrophic regular non-atypical 
nuclei and presence of microfollicular pattern, with 
or without oncocytic (Hürthle) cell change and scant 
colloid.
suspicious for malignancy
•	 Suspicious for papillary carcinoma: aspirates of 
moderate-to-high cellularity and equivocal featu-
res of malignancy, such as enlarged and irregular 
nuclei, occasional presence of nuclear folds but 
no cytoplasmic inclusions. 
•	 Suspicious for follicular carcinoma: it includes 
also aspirates with microfollicular cytology with 
nuclear atypia and follicular oncocytic cells tu-
mors. The diagnosis Hürthle-cell neoplasm/
follicular neoplasm with oncocytic features car-
ries a higher risk of malignancy as compared with 
a diagnosis of follicular lesion/neoplasm (32). 
malignant
•	 Papillary carcinoma and variants: includes as-
pirates with high cellularity and cytologically 
malignant cells, tumor cells arranged in sheets, 
follicular and papillary architecture, and nuclear 
abnormalities such as intranuclear cytoplasmic 
inclusions and grooves.
•	 Medullary carcinoma: characterized by tumor 
cells that are notably non-cohesive and polymor-
phic (e.g., plasmacytoid, angular), and nuclei that 
are hyperchromatic, located at one pole of the 
cell and, eventually, with cytoplasmic inclusions.
•	 Poorly differentiated and anaplastic carcinomas: 
it includes aspirates with insular pattern; cells of 
anaplastic carcinoma are usually large and bizarre. 
unsatisfactory
Cases of limited cellularity or poor preservation and 
fixation. A specimen is qualified as satisfactory if pre-
senting at least six to eight groups of well-preserved 
follicular cells with ten or more cells per group. The 
acceptable prevalence of unsatisfactory cytologies varies 
between 10% to 15%.
Routine repeat biopsy is not recommended for nodules 
diagnosed as benign on FNAB; however, it may be consi-
dered if there is clinical or US evidence of nodular growth 
(> 20% increase in volume) or if the nodule presents re-
current cystic degeneration.
therApy
suppressive therapy
Despite the lack of beneficial evidence for suppressive 
therapy with levothyroxine (L-T4) or triiodothyronine 
LATS recommendations for thyroid nodules
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(T3) in decreasing the size of benign thyroid nodules, 
this treatment is used by some centers based on indi-
vidual experience. Therapy with L-T4 may be helpful 
in preventing the development of novel nodules in the 
contralateral lobe or the development of goiter after 
lobectomy for follicular adenomas (33). Suppressive 
therapy is contraindicated in autonomous thyroid no-
dules, older patients and in those in whom suppression 
with L-T4 may present a potential hazardous risk – par-
ticularly patients with bone or cardiovascular disease. 
The panel does not recommend suppressive therapy 
with L-T4 or T3 for benign nodules.
percutaneous ethanol injection
There is limited experience on the treatment of solid 
thyroid nodules with percutaneous ethanol injection 
(PEI). However, some reports have shown encourag-
ing results (34). This method has been used with ac-
ceptable results in patients with toxic adenomas (35).
The panel does not recommend PEI for routine treatment 
of thyroid nodules other than cysts.
radioiodine treatment of nodular goiter 
Radioiodine therapy has been used for treatment of 
multinodular goiter in patients unsuitable for surgical 
treatment since the late 1980’s. According to some stu-
dies, the decrease in goiter size induced by radioiodine 
can reach up to 40% (36-41). It is considered an al-
ternative therapy for elderly patients with large goiters 
and/or at risk for surgery. 
The use of rhTSH to increase radioiodine uptake 
and obtain a more uniform isotope distribution within 
the goiter has been considered over the past decade 
(42). Several doses of rhTSH have been tested yielding 
similar results, with an average reduction in gland size 
of 40% to 50% over 6 to 12 months (43-47). New stu-
dies are necessary to address the adequate rhTSH dose 
and the correct radioiodine dose to obtain the best re-
sults with lowest adverse events (thyrotoxicosis, goiter 
enlargement or local pain). 
The panel considers the radioiodine treatment of no-
dular goiter as an alternative therapy for patients with 
large goiters.
surgery 
Surgery should be performed in patients with malig-
nant or clinically concerning nodules with suspicious 
or indeterminate cytology, in recurrent cystic nodules, 
and when there are esthetic, compressive symptoms or 
follow-up concerns (48). 
Surgical options include lobectomy plus isthmectomy for 
solitary benign thyroid nodules and total thyroidectomy for 
multinodular goiters, suspicious and malignant nodules.
experimental therapies
It has been recently described that higher circulating le-
vels of insulin may cause increased thyroid proliferation 
and the formation of nodules (49). Insulin resistance 
syndrome has also been implicated as an important fac-
tor for cell proliferation (50,51). Metformin treatment 
is associated with significant improvement of insulin 
resistance and could be another therapeutic tool in pa-
tients with thyroid nodules and insulin resistance. 
Interstitial laser thermal ablation and percutaneous 
radiofrequency thermal ablation are new nonsurgical 
therapeutic options for benign thyroid nodules. Both 
methods induce nodule shrinkage and improvement in 
local symptoms (52,53). 
All these therapies are still experimental and their in-
dications still need to be defined. 
follow-up
Follow-up of patients with thyroid nodule should be 
performed every 12 months with clinical and US exa-
minations to reassess the size of the nodule. Nodules 
that present with growth, defined by an increase in vo-
lume > 20% or of 15% to 20% in the greater diameter by 
US examination performed with the same equipment 
(54) should be reevaluated by FNAB, considering that 
a first FNAB evaluation carries a 5% possibility of false 
negativity (55,56). In case the size of the nodule re-
mains unchanged after three assessments, the follow-up 
interval may be prolonged.
Benign thyroid nodules should be followed with serial 
ultrasound examination at 12- to 18-month intervals. 
thyroID noDules In chIlDren 
The occurrence of thyroid nodules is uncommon in 
children and adolescents compared with adults, but 
when present, carry a higher risk of malignancy (14% to 
40% in children compared with 5% in adults) (57-60).
The effectiveness of FNAB in children is similar to 
that observed in adults, suggesting that FNAB may be 
equally effective in selecting younger patients for sur-
gery with low risk of missing malignant lesions (61-64).
LATS recommendations for thyroid nodules
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All thyroid nodules > 0.5 cm in children must be 
evaluated with FNAB. The diagnostic steps for thyroid 
nodules in children and adolescents are similar to those 
for adults.
In children and adolescents, L-T4 therapy for be-
nign nodules has some benefits, but efficacy is fairly 
low. Recent guidelines have addressed L-T4 therapy for 
small thyroid nodules diagnosed as benign on FNAB 
in children and adolescents. In considering L-T4 tre-
atment, complete TSH suppression (< 0.1 mU/L) 
should be avoided. Usually, there is nodular regrowth 
after discontinuation of L-T4; however, if this occurs 
during L-T4 treatment another FNAB and surgery 
should be considered (65).
Thyroidectomy for benign nodules (usually restric-
ted to lobectomy) remains the most effective treatment 
modality for this group of patients. This is also true for 
cystic thyroid nodules in childhood (66).
The diagnostic and therapeutic approach to thyroid 
nodules in children should be the same as in adults.
thyroID noDules DurIng pregnAncy 
Between 11% and 15% of women develop new thyroid 
nodules during pregnancy. In areas of mild iodine in-
sufficiency, preexisting nodules tend to increase in size 
during this period. The prevalence of thyroid nodules is 
significantly higher in women who have been pregnant 
compared with those with no previous pregnancies. 
The diagnostic approach of a thyroid nodule disco-
vered during pregnancy is similar to that in non-preg-
nant patients. However, most pregnant patients with 
a newly discovered thyroid nodule can safely undergo 
diagnostic studies as well as therapy after delivery when 
surgery can be performed without risk to the fetus 
(67). Exceptions to this rule are rapidly growing nodu-
les and patients with extreme anxiety. The decision to 
operate during pregnancy should take into considera-
tion the patient’s attitude about forestalling treatment 
until postpartum as well as concerns about fetal risk. 
If the ultimate decision is to perform surgery during 
pregnancy, it should be avoided during the first and 
third trimesters, but rather, be performed during the 
second trimester (before fetal viability) which appears 
to be safer for both the patient and the fetus.
In all pregnant patients with thyroid nodules, 
thyroid function tests should be performed for detec-
tion of hypo- or hyperthyroidism. Thyroid ultrasound 
is a useful tool to characterize and monitor growth of 
thyroid lesions, detect thyroiditis and delineate the pre-
sence of suspicious lymph nodes in these patients. Ra-
dionuclide scanning of the thyroid is contraindicated 
during this period. 
The panel recommends that the diagnosis and treat-
ment of thyroid nodule that occurs during pregnancy be 
delayed until after delivery in most patients.
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